Added to YB: 2025-01-31
Pitch date: 2025-01-30
ACOG [bullish]
Alpha Cognition Inc.
-13.8%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.
Market Cap
$124.2M
Pitch Price
$6.16
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.15
P/E
-4.49
EV/Sales
11.95
Sector
Biotechnology
Category
growth
Show full summary:
Alpha Cognition (ACOG): High Potential as ZUNVEYL Nears 2025 Launch
ACOG: ZUNVEYL, Galantamine prodrug for AD, avoids GI side effects. Targets LTC market (70% AD, 50% intolerant). $2B TAM, $101M cap. 88% LTCs likely to prescribe. Launch Mar 2025, breakeven in 3yrs. Phase 4 & sublingual coming. Long if execution succeeds.
Read full article (1 min)